Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 2
2006 1
2007 2
2008 3
2009 2
2010 2
2011 4
2012 4
2013 3
2014 4
2015 2
2016 5
2017 5
2018 4
2019 3
2020 4
2021 3
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.
Schneider AK, Domingos-Pereira S, Cesson V, Polak L, Fallon PG, Zhu J, Roth B, Nardelli-Haefliger D, Derré L. Schneider AK, et al. Among authors: nardelli haefliger d. Front Immunol. 2024 Jan 12;14:1335326. doi: 10.3389/fimmu.2023.1335326. eCollection 2023. Front Immunol. 2024. PMID: 38283350 Free PMC article.
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D. Derré L, et al. Among authors: nardelli haefliger d. J Immunother Cancer. 2023 Dec 14;11(12):e008020. doi: 10.1136/jitc-2023-008020. J Immunother Cancer. 2023. PMID: 38101861 Free PMC article.
Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.
Domingos-Pereira S, Sathiyanadan K, Polak L, Haefliger JA, Schmittnaegel M, Ries CH, Jichlinski P, Roth B, Derré L, Nardelli-Haefliger D. Domingos-Pereira S, et al. Among authors: nardelli haefliger d. Int J Mol Sci. 2022 Dec 21;24(1):123. doi: 10.3390/ijms24010123. Int J Mol Sci. 2022. PMID: 36613562 Free PMC article.
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I, Derré L, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias S, Dartiguenave F, Masnada A, Texeira-Pereira C, Benmerzoug S, Chevalier M, Domingos-Pereira S, Nguyen S, Polak L, Schneider A, Roth B, Jichlinski P, Nardelli-Haefliger D. Lucca I, et al. Among authors: nardelli haefliger d. Eur Urol Open Sci. 2022 Oct 3;45:55-58. doi: 10.1016/j.euros.2022.09.004. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36212980 Free PMC article.
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S, Chevalier MF, Benmerzoug S, Cesson V, Schneider AK, Rodrigues-Dias SC, Dartiguenave F, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Nguyen S, et al. Among authors: nardelli haefliger d. J Immunother Cancer. 2022 Aug;10(8):e004880. doi: 10.1136/jitc-2022-004880. J Immunother Cancer. 2022. PMID: 36002184 Free PMC article.
Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.
Moreo E, Uranga S, Picó A, Gómez AB, Nardelli-Haefliger D, Del Fresno C, Murillo I, Puentes E, Rodríguez E, Vales-Gómez M, Pardo J, Sancho D, Martín C, Aguilo N. Moreo E, et al. Among authors: nardelli haefliger d. J Immunother Cancer. 2022 Jul;10(7):e004325. doi: 10.1136/jitc-2021-004325. J Immunother Cancer. 2022. PMID: 35781395 Free PMC article.
Targeting Endothelial Connexin37 Reduces Angiogenesis and Decreases Tumor Growth.
Sathiyanadan K, Alonso F, Domingos-Pereira S, Santoro T, Hamard L, Cesson V, Meda P, Nardelli-Haefliger D, Haefliger JA. Sathiyanadan K, et al. Among authors: nardelli haefliger d. Int J Mol Sci. 2022 Mar 8;23(6):2930. doi: 10.3390/ijms23062930. Int J Mol Sci. 2022. PMID: 35328350 Free PMC article.
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Villier L, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: nardelli haefliger d. Eur Urol Open Sci. 2021 Nov 18;34:79-82. doi: 10.1016/j.euros.2021.10.001. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34825225 Free PMC article.
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Verardo M, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: nardelli haefliger d. Eur Urol Focus. 2022 May;8(3):748-751. doi: 10.1016/j.euf.2021.06.001. Epub 2021 Jun 17. Eur Urol Focus. 2022. PMID: 34147404 Free article.
57 results